Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
|Articles|May 1, 2018
Biologics at USP
USP strives to advance quality throughout the public health framework with standards.
Advertisement
USP strives to advance quality throughout the public health framework with standards. Safeguarding the integrity of the global supply chain end-to-end is fundamental to protecting the public’s health, especially as products come from all over the world.
Products and Services
Manufacturers must ensure the purity and quality of the biologics that make their way to patients. USP is a global leader in the development of quality standards for biologics that assist manufacturers by increasing predictability and reliability, and preserving the integrity of the global supply chain.
12601 Twinbrook Pkwy, Rockville, MD 20852
[email protected]
tel. 800. 227.8772
Advertisement
Related to this article
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
IMVT-1402 (imeroprubart) failed to reach statistical significance on CLASI-A at Week 12 in a 57-patient proof-of-concept study, and Immunovant will stop development in cutaneous lupus erythematosus. The anti-FcRn antibody continues in five other autoimmune indications.
SOTIO Biotech's LRRC15-targeted antibody-drug conjugate SOT106 now holds both Orphan Drug and Fast Track Designations in soft tissue sarcoma and osteosarcoma. The company expects to start first-in-human testing later in 2026.
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
Johnson & Johnson's modeling projects 18.5-year life expectancy with Tecvayli-Darzalex versus 4.9 years for standard care.
Advertisement
Advertisement